Targeting the BRAF pathway in haematological diseases
- Author(s)
- Rees, MJ; Dickinson, M; Paterson, J; Ng, TF; Grigg, A; Moore, J; Blombery, P; Seymour, JF;
- Details
- Publication Year 2023-05,Volume 53,Issue #5,Page 845-849
- Journal Title
- Internal Medicine Journal
- Publication Type
- Research article
- Abstract
- Since the recognition of BRAF V600E mutations in the majority of cases of hairy cell leukaemia, Erdheim-Chester disease and Langerhans cell histiocytosis, the targeted oral kinase inhibitors dabrafenib and vemurafenib have been adapted for their treatment. Like other targeted agents, these drugs produce high response rates and predictable but unique side effects. Physician familiarity is essential for the effective use of these agents. We review the Australian experience of BRAF/MEK inhibitor therapy in these rare haematological cancers.
- Publisher
- Wiley
- Keywords
- Humans; Australia; Proto-Oncogene Proteins B-raf; *Hematologic Diseases; *Hematologic Neoplasms; *Drug-Related Side Effects and Adverse Reactions
- Department(s)
- Clinical Haematology; Pathology
- PubMed ID
- 37222093
- Publisher's Version
- https://doi.org/10.1111/imj.16091
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-09-05 06:33:26
Last Modified: 2024-07-16 04:21:56